Evolutionary optimization of production materials workflow processes

AbstractWe present an evolutionary optimisation technique for stochastic production processes, which is able to find improved production materials workflow processes with respect to arbitrary combinations of numerical quantities associated with the production process. Working from a core fragment of the BPMN language, we employ an evolutionary algorithm where stochastic model checking is used as a fitness function to determine the degree of improvement of candidate processes derived from the original process through mutation and cross-over operations. We illustrate this technique using a case study where a baked goods company seeks to improve production time while simultaneously minimising the cost and use of resources

The Anti-Circumvention Provision of The Digital Millennium Copyright Act

The DMCA\u27s ban on circumvention technology, however, has been the subject of some dispute. In the arms race between encryption and decryption technologies, the anti-circumvention provision seems to have recently won out. The anti-circumvention provision also appears to have altered the contours of copyright law and to have disturbed the balance between protecting the rights of authors and promoting the advancement and flow of information. This Article begins with a brief history of the Digital Millennium Copyright Act and its anti-circumvention provision. It then describes the features of the anti-circumvention provision, its exceptions, and the remedies provided by the Act. Finally, it reviews three recent cases that raise important issues that, when ultimately resolved, may permanently affect copyright law

Muc5ac: a critical component mediating the rejection of enteric nematodes

The mucin Muc5ac is essential for the expulsion of Trichuris muris and other gut-dwelling nematodes

Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle

Polyclonal antibodies, derived from humans or hyperimmunized animals, have been used prophylactically or therapeutically as countermeasures for a variety of infectious diseases. SAB Biotherapeutics has successfully developed a transchromosomic (Tc) bovine platform technology that can produce fully human immunoglobulins rapidly, and in substantial quantities, against a variety of disease targets. In this study, two Tc bovines expressing high levels of fully human IgG were hyperimmunized with a recombinant glycoprotein (GP) vaccine consisting of the 2014 Ebola virus (EBOV) Makona isolate. Serum collected from these hyperimmunized Tc bovines contained high titers of human IgG against EBOV GP as determined by GP specific ELISA, surface plasmon resonance (SPR), and virus neutralization assays. Fully human polyclonal antibodies against EBOV were purified and evaluated in a mouse challenge model using mouse adapted Ebola virus (maEBOV). Intraperitoneal administration of the purified anti-EBOV IgG (100 mg/kg) to BALB/c mice one day after lethal challenge with maEBOV resulted in 90% protection; whereas 100% of the control animals succumbed. The results show that hyperimmunization of Tc bovines with EBOV GP can elicit protective and potent neutralizing fully human IgG antibodies rapidly and in commercially viable quantities